
United Therapeutics Misses Q2 EPS, Revenues Beat
United Therapeutics (NASDAQ:UTHR) reported Q2 EPS of $2.41, $1.97 worse than the analyst estimate of $4.38. Revenue for the quarter came in at $466.9 million versus the consensus estimate of...
United Therapeutics (NASDAQ:UTHR) reported Q2 EPS of $2.41, $1.97 worse than the analyst estimate of $4.38. Revenue for the quarter came in at $466.9 million versus the consensus estimate of...
By Vlad Schepkov Shares of United Therapeutics (NASDAQ:UTHR) quickly climbed the list of Monday, May 23rd's top gainers and most active stocks, finishing the day nearly 12% higher, following...
United Therapeutics (NASDAQ:UTHR) reported Q1 EPS of $5.03, $1.69 better than the analyst estimate of $3.34. Revenue for the quarter came in at $461.9 million versus the consensus estimate...
By Sam Boughedda Investing.com — The U.S. Food and Drug Administration did not approve United Therapeutics Corporation's (NASDAQ:UTHR), application with MannKind Corp . (NASDAQ:MNKD) for...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.